Sugi Predict

Sugi Predict / Compounds / SCHEMBL74655

SCHEMBL74655

SCHEMBL74655

CCC(C(=O)O)c1ccc2sc3nc(-c4ccc(N)cc4)cn3c2c1

nearest known ligand 0.43

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.42
▸ LMNA P02545 5/20 0.42
▸ TP53 P04637 4/20 0.42
▸ ALDH1A1 P00352 3/20 0.40
▸ RAB9A P51151 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ NPC1 O15118 2/20 0.40
▸ ATM Q13315 2/20 0.40
▸ TSHR P16473 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ RXFP1 Q9HBX9 2/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ FLT3 P36888 1/20 0.39
▸ THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL74654 0.92 LMNA (0.48) MAPTLMNATP53ALDH1A1RAB9A
SCHEMBL74190 0.78 FLT3 (0.71) FLT3
SCHEMBL3453283 0.78 KDM4E (0.44) MAPTLMNATP53RAB9ASMN1; SMN2
SCHEMBL20303359 0.77 FLT3 (0.46) MAPTLMNATP53ALDH1A1RAB9A
SCHEMBL3864619 0.74 LMNA (0.50) MAPTLMNATP53RAB9ASMN1; SMN2
SCHEMBL11013010 0.74 MAPT (0.56) MAPTLMNATP53ALDH1A1RAB9A
SCHEMBL772567 0.74 MAPT (0.63) MAPTLMNATP53ALDH1A1RAB9A
SCHEMBL73288 0.73 MAPT (0.48) MAPTLMNATP53ALDH1A1RAB9A
SCHEMBL72902 0.73 AKR1C3 (0.47) MAPTLMNATP53RAB9ASMN1; SMN2
SCHEMBL13054386 0.71 LMNA (0.55) MAPTLMNATP53ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8921546-B2 Imidazolothiazole compounds for the treatment of disease AMBIT BIOSCIENCES CORPORATION (US) 2014-12-30 — — US disclosed
US-20140243525-A1 IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE AMBIT BIOSCIENCES CORPORATION (US) 2014-08-28 — — US disclosed
US-8557810-B2 Imidazolothiazole compounds for the treatment of disease AMBIT BIOSCIENCES CORPORATION (US) 2013-10-15 — — US disclosed
US-20120129850-A1 IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE AMBIT BIOSCIENCES CORPORATION 2012-05-24 — — US disclosed
US-8129374-B2 Method of using imidazolothiazole compounds for the treatment of disease AMBIT BIOSCIENCE CORPORATION (US) 2012-03-06 — — US disclosed
US-20070232604-A1 receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors AMBIT BIOSCIENCES CORPORATION 2007-10-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243525-A1 IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE GRK2, GRK4, GRK3 MAPT 1188/4885LMNA 3036/4885TP53 743/4885
US-20120129850-A1 IMIDAZOLOTHIAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASE GRK2, GRK4, GRK3 MAPT 1188/4885LMNA 3036/4885TP53 743/4885
US-20070232604-A1 receptor kinase inhibitors such as 3-(2-{4-[3-(5-tert-Butyl-isoxazol-3-yl)-ureido]-phenyl}-benzo[d]imidazo[2,1-b]thiazol-7-yl)-N-(2-morpholin-4-yl-ethyl)-propionamide; flk inhibitors GRK2, GRK3, BLK MAPT 1520/4885LMNA 1744/4885TP53 2708/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.